Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUVED + REIMMUGEN is an integrative Ayurvedic combination therapy developed by SUPRA Health Solutions LLP for the treatment of various vascular diseases, including coronary artery disease (CAD), cardiovascular disease (CVD), stroke (CVA), deep vein thrombosis (DVT), and peripheral arterial disease (PAD). SUVED is a polyherbal extract (ghana) formulation containing herbs such as Terminalia arjuna, Withania somnifera, and Terminalia chebula, which are traditionally used for their cardiotonic, antioxidant, and potential clot-dissolving properties. REIMMUGEN consists of whole bovine colostrum, which is rich in immunoglobulins (IgA, IgG, IgM, IgE, IgD), growth factors (including vascular endothelial growth factor and epidermal growth factor), and lactoferrin. This combination is intended to enhance immunity, support endothelial repair, and provide cardioprotective effects when administered alongside conventional medical therapies. It has been evaluated in double-blind, placebo-controlled clinical trials in India for vascular conditions and COVID-19.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SUVED + REIMMUGEN.